Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
IGF-1R inhibitor
DRUG CLASS:
IGF-1R inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
BMS-754807 (10)
AMG 479 (10)
ASP7487 (7)
AZD3463 (2)
GSK 1838705A (2)
SY-707 (1)
CP-751,871 (1)
BMS-536924 (0)
FPI-1434 (0)
IGV-001 (0)
KW-2450 (0)
LX-101 (0)
NVP-ADW742 (0)
NVP-AEW541 (0)
NVP-TAE226 (0)
teprotumumab-trbw (0)
XL228 (0)
IMC A12 (0)
MK 0646 (0)
MEDI-573 (0)
MM-141 (0)
AXL1717 (0)
SCH 717454 (0)
BMS-754807 (10)
AMG 479 (10)
ASP7487 (7)
AZD3463 (2)
GSK 1838705A (2)
SY-707 (1)
CP-751,871 (1)
BMS-536924 (0)
FPI-1434 (0)
IGV-001 (0)
KW-2450 (0)
LX-101 (0)
NVP-ADW742 (0)
NVP-AEW541 (0)
NVP-TAE226 (0)
teprotumumab-trbw (0)
XL228 (0)
IMC A12 (0)
MK 0646 (0)
MEDI-573 (0)
MM-141 (0)
AXL1717 (0)
SCH 717454 (0)
›
Associations
(40)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (AEWS1221) (NCT02306161)
Phase 3
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/06/2025
Initiation :
12/12/2014
Primary completion :
03/31/2021
Completion :
09/19/2025
EGFR
|
doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma (NCT04485949)
Phase 2
Imvax
Imvax
Active, not recruiting
Phase 2
Imvax
Active, not recruiting
Last update posted :
05/31/2024
Initiation :
03/20/2023
Primary completion :
01/01/2025
Completion :
07/01/2027
MGMT
|
temozolomide • IGV-001
Palbociclib + Ganitumab In Ewing Sarcoma (NCT04129151)
Phase 2
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Completed
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
02/14/2023
Initiation :
12/05/2019
Primary completion :
12/15/2022
Completion :
12/15/2022
CDK4 • EWSR1 • IGF1 • FLI1 • FUS
|
Ibrance (palbociclib) • ganitumab (AMG 479)
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer (NCT01154335)
Phase 1
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Completed
Phase 1
SCRI Development Innovations, LLC
Completed
Last update posted :
05/03/2022
Initiation :
07/01/2010
Primary completion :
05/01/2013
Completion :
05/01/2013
KRAS • ALK
|
KRAS mutation • KRAS wild-type • RAS wild-type
|
everolimus • linsitinib (ASP7487)
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00617708)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
02/08/2022
Initiation :
03/01/2008
Primary completion :
09/01/2012
Completion :
02/25/2014
EGFR
|
erlotinib • gemcitabine • cixutumumab (IMC A12)
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (NCT01446159)
Phase 1b/2
MedImmune LLC
MedImmune LLC
Completed
Phase 1b/2
MedImmune LLC
Completed
Last update posted :
06/02/2020
Initiation :
06/13/2011
Primary completion :
06/28/2019
Completion :
06/28/2019
HER-2 • IGF2
|
exemestane • dusigitumab (MEDI-573)
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer (NCT00684983)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
03/24/2020
Initiation :
07/30/2008
Primary completion :
01/07/2014
Completion :
10/15/2019
HER-2
|
HER-2 positive • HER-2 amplification
|
Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)
Preoperative Treatment With Cetuximab and/or IMC-A12 (NCT00957853)
Phase 2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Completed
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
03/19/2020
Initiation :
10/17/2011
Primary completion :
08/15/2018
Completion :
08/15/2018
EGFR
|
Erbitux (cetuximab) • cixutumumab (IMC A12)
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) (NCT00889382)
Phase 1/2
Astellas Pharma Inc
Astellas Pharma Inc
Completed
Phase 1/2
Astellas Pharma Inc
Completed
Last update posted :
11/19/2019
Initiation :
08/05/2009
Primary completion :
08/01/2014
Completion :
08/25/2014
MUC16
|
MUC16 elevation
|
paclitaxel • linsitinib (ASP7487)
A Study in Non-Small Cell Lung Cancer (NCT01232452)
Phase 2
Eli Lilly and Company
Eli Lilly and Company
Completed
Phase 2
Eli Lilly and Company
Completed
Last update posted :
09/20/2019
Initiation :
04/01/2011
Primary completion :
01/01/2013
Completion :
06/01/2016
IGF1 • IGFBP3
|
cisplatin • pemetrexed • cixutumumab (IMC A12)
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer (NCT00781911)
Phase 2
Eli Lilly and Company
Eli Lilly and Company
Completed
Phase 2
Eli Lilly and Company
Completed
Last update posted :
09/20/2019
Initiation :
02/01/2009
Primary completion :
07/01/2011
Completion :
05/01/2016
IGF1 • IGF2
|
cixutumumab (IMC A12) • octreotide acetate solution for injection
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer (NCT01263782)
Phase 2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Completed
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
05/15/2019
Initiation :
05/17/2011
Primary completion :
08/15/2017
Completion :
08/15/2017
EGFR • ALK
|
EGFR mutation • ALK fusion
|
Avastin (bevacizumab) • carboplatin • pemetrexed • cixutumumab (IMC A12)
A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors (NCT00816361)
Phase 1
MedImmune LLC
MedImmune LLC
Completed
Phase 1
MedImmune LLC
Completed
Last update posted :
03/04/2019
Initiation :
03/09/2009
Primary completion :
09/11/2012
Completion :
09/11/2012
IGF1 • IGF2
|
dusigitumab (MEDI-573)
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene (NCT01221077)
Phase 2
Astellas Pharma Inc
Astellas Pharma Inc
Completed
Phase 2
Astellas Pharma Inc
Completed
Last update posted :
01/24/2019
Initiation :
04/08/2011
Primary completion :
03/01/2013
Completion :
09/01/2014
EGFR
|
EGFR mutation • EGFR exon 19 deletion
|
erlotinib • linsitinib (ASP7487)
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
12/11/2018
Initiation :
06/18/2012
Primary completion :
04/01/2014
Completion :
04/01/2014
mTOR • IR
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer (CARRIE) (NCT02399137)
Phase 2
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Completed
Phase 2
Merrimack Pharmaceuticals
Completed
Last update posted :
09/18/2018
Initiation :
05/01/2015
Primary completion :
08/01/2018
Completion :
08/01/2018
IGF1
|
gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy (NCT01186861)
Phase 2
Astellas Pharma Inc
Astellas Pharma Inc
Completed
Phase 2
Astellas Pharma Inc
Completed
Last update posted :
09/05/2018
Initiation :
03/04/2011
Primary completion :
07/01/2013
Completion :
03/11/2015
EGFR
|
EGFR mutation
|
erlotinib • linsitinib (ASP7487)
A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) (NCT00759785)
Phase 1
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
08/15/2018
Initiation :
09/30/2008
Primary completion :
02/17/2010
Completion :
02/17/2010
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR negative
|
dalotuzumab (MK 0646)
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) (NCT00614393)
Phase 2
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 2
Merck Sharp & Dohme LLC
Completed
Last update posted :
08/08/2018
Initiation :
12/24/2007
Primary completion :
06/01/2010
Completion :
03/07/2012
KRAS
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression
|
Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy (NCT00503685)
Phase 2
Eli Lilly and Company
Eli Lilly and Company
Completed
Phase 2
Eli Lilly and Company
Completed
Last update posted :
06/06/2018
Initiation :
06/01/2007
Primary completion :
03/01/2009
Completion :
03/01/2009
KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3
|
KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1
|
Erbitux (cetuximab) • cixutumumab (IMC A12)
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer (NCT00728949)
Phase 2
Eli Lilly and Company
Eli Lilly and Company
Completed
Phase 2
Eli Lilly and Company
Completed
Last update posted :
06/06/2018
Initiation :
08/01/2008
Primary completion :
03/01/2012
Completion :
02/01/2015
ER • PGR
|
tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • cixutumumab (IMC A12)
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT01182883)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Withdrawn
Phase 1
National Cancer Institute (NCI)
Withdrawn
Last update posted :
07/02/2017
Initiation :
07/28/2010
Primary completion :
04/04/2012
Completion :
04/04/2012
AFP
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (NCT01234857)
Phase 2
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 2
Merck Sharp & Dohme LLC
Completed
Last update posted :
05/31/2017
Initiation :
09/17/2010
Primary completion :
10/15/2013
Completion :
10/15/2013
HER-2 • ER
|
ER positive • HER-2 negative
|
exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)
Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550)
Phase 1
Centaurus Biopharma Co., Ltd.
Centaurus Biopharma Co., Ltd.
Unknown status
Phase 1
Centaurus Biopharma Co., Ltd.
Unknown status
Last update posted :
03/09/2017
Initiation :
03/01/2016
Primary completion :
03/01/2018
Completion :
03/01/2018
ALK
|
ALK positive • ALK rearrangement
|
Xalkori (crizotinib) • conteltinib (SY-707)
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma (NCT00813605)
Phase 2
NantCell, Inc.
NantCell, Inc.
Completed
Phase 2
NantCell, Inc.
Completed
Last update posted :
10/27/2016
Initiation :
03/01/2009
Primary completion :
01/01/2011
Completion :
06/01/2012
KRAS
|
KRAS mutation
|
5-fluorouracil • irinotecan • leucovorin calcium • ganitumab (AMG 479) • conatumumab (AMG 655)
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (NCT01473303)
Phase 2
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Withdrawn
Phase 2
Alliance for Clinical Trials in Oncology
Withdrawn
Last update posted :
06/28/2016
Initiation :
08/01/2012
Primary completion :
08/01/2012
UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
|
5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ganitumab (AMG 479)
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) (NCT00729742)
Phase 1
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
04/04/2016
Initiation :
02/01/2009
Primary completion :
06/01/2010
Completion :
05/01/2011
EGFR
|
EGFR mutation • EGFR amplification
|
erlotinib • dalotuzumab (MK 0646)
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer (NCT00719212)
Phase 2
Translational Research in Oncology
Translational Research in Oncology
Completed
Phase 2
Translational Research in Oncology
Completed
Last update posted :
01/11/2016
Initiation :
01/01/2009
Primary completion :
05/01/2013
Completion :
05/01/2013
MUC16
|
MUC16 elevation
|
ganitumab (AMG 479)
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer (NCT00678769)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
11/04/2015
Initiation :
05/01/2008
Primary completion :
06/01/2013
Completion :
10/01/2015
PTEN • AKT1 • KDR • IRS1
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer (NCT00678626)
Phase 2
Pfizer
Pfizer
Withdrawn
Phase 2
Pfizer
Withdrawn
Last update posted :
05/04/2015
Initiation :
04/01/2009
Primary completion :
09/01/2011
Completion :
09/01/2011
HER-2
|
docetaxel • figitumumab (CP-751,871)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login